• All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

(Unaudited Financial Data) Significant Sales and EBITDA Growth – Strong increase in net profit   Paiania, 19 March 2025 - Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date: Consolidated Sales from ongoing...

Paiania, 14 March 2025 – Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2025, as follows:   Wednesday, 19 March 2025 Flash Note on Financial Results of FY 2024 Thursday, 3 April 2025 Announcement of FY 2024 Financial Report Thursday, 24...